- Q4 2023 Sedana Medical AB (publ) Earnings Call TranscriptFeb 15, 2024kr18.93 (-5.11%)Earnings
- Q3 2023 Sedana Medical AB (publ) Earnings Call TranscriptOct 26, 2023kr17.23 (-4.44%)Earnings
- Q2 2023 Sedana Medical AB (publ) Earnings Call TranscriptJul 21, 2023kr24.64 (+10.69%)Earnings
- Q1 2023 Sedana Medical AB (publ) Earnings Call TranscriptApr 27, 2023kr24.92 (+7.69%)Earnings
- Q4 2022 Sedana Medical AB (publ) Earnings Call TranscriptFeb 16, 2023kr23.68 (+11.38%)Earnings
- Sedana Medical AB (publ) at Redeye Medtech Seminar (Virtual) TranscriptOct 26, 2022
- Q3 2022 Sedana Medical AB (publ) Earnings Call TranscriptOct 25, 2022kr20 (-21.94%)Earnings
- Q2 2022 Sedana Medical AB (publ) Earnings Call TranscriptJul 21, 2022kr24.02 (+9.68%)Earnings
- Q1 2022 Sedana Medical AB (publ) Earnings Call TranscriptApr 28, 2022kr33.9 (-30.82%)Earnings
- Q4 2021 Sedana Medical AB (publ) Earnings Call TranscriptFeb 17, 2022kr71.35 (+2.51%)Earnings
- Q3 2021 Sedana Medical AB (publ) Earnings Call TranscriptNov 04, 2021kr88.05 (+7.38%)Earnings
- Q2 2021 Sedana Medical AB (publ) Earnings Call TranscriptAug 19, 2021kr82.45 (-3.90%)Earnings
- Q1 2021 Sedana Medical AB (publ) Earnings Call TranscriptMay 06, 2021kr82.25 (-3.80%)Earnings
- Full Year 2020 Sedana Medical AB (publ) Earnings Call TranscriptFeb 25, 2021kr91 (+2.97%)Earnings
Q2 2021 Sedana Medical AB (publ) Earnings Call Transcript
Hello, and welcome to the Sedana Medical Q2 Report 2021. (Operator Instructions)
Today, I'm pleased to present acting CEO, Jens Lindberg. Please begin your meeting.
()-&
Thank you. And hi, and welcome, everyone. So for today's report, I will be joined by our CFO, Susanne Andersson; and our Chief Medical Officer, Peter Sackey.
So with that, let's get on with it, and we can move to the next slide, please, which is our disclaimer slide, which I guess we can move through relatively quickly. It's impossible to -- move the slides, please. There we go. And then the disclaimer slide, we can move to the next one as well, and I'll start with the quarterly highlights.
So this year, so if we look at Q2 and we look back, a couple of things. Clearly, first and foremost, quite happy about the approval of Sedaconda. We received the DCP approval in sort of July and then subsequently, the first national approval in France.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)